Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The current selected U.S. label and historical handbook differ in administration and available renal evidence. Immune-mediated nephritis requires toxicity management, not an automatic routine renal-dose reduction.
Check source scope before reading a dose
GlobalRPh RX List - Yervoy
Product / population
Adult product-specific renal information; not a complete prescribing regimen.
Renal method
CTCAE creatinine-toxicity grades, not a renal clearance dosing table.
Source revision
May 2025 on retrieved RX page
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Immune nephritis requires toxicity management, not a calculated dose reduction
The new RX section describes withholding or stopping treatment for immune-mediated creatinine toxicity. These CTCAE grades are not the baseline kidney-function categories used in pharmacokinetic assessment.
What to reconcile: Use the oncology toxicity-management protocol for treatment-emergent nephritis, including the combination-treatment rules. Do not reinterpret a baseline no-adjustment statement as permission to continue through significant immune toxicity.
GlobalRPh-hosted RX List · Adult product-specific renal information; not a complete prescribing regimen.
Renal method: CTCAE creatinine-toxicity grades, not a renal clearance dosing table. Source date: May 2025 on retrieved RX page Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Monitoring or renal-toxicity guidance. This finding concerns risk or surveillance; it may not establish a dose adjustment.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For immune-mediated nephritis, withhold YERVOY for grade 2 or 3 blood-creatinine elevation and permanently discontinue for grade 4. Routine dose reduction is not the strategy. In combination with nivolumab, the source directs withholding or discontinuing both agents for toxicity. Resumption requires complete or partial resolution to grade 0-1 after corticosteroid taper; persistent toxicity or inability to taper as specified requires permanent discontinuation. Follow the complete oncology toxicity protocol. These toxicity grades are not CrCl dose bands.
RDM34-rxlist-yervoy-drug-C1 · Source locator: Dosage modifications for adverse reactions, Table 3 and footnote a; immune-mediated nephritis.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.